AstraZeneca VOLGA Trial Boosts Bladder Cancer Survival
CAMBRIDGE, UK, May 14, 2026 AstraZeneca announced positive interim results from the global Phase III VOLGA trial, demonstrating that...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, UK, May 14, 2026 AstraZeneca announced positive interim results from the global Phase III VOLGA trial, demonstrating that...
RAMAT-GAN, Israel, May 14, 2026 Galmed Pharmaceuticals Ltd. announced positive results from its first-in-human pharmacokinetics study evaluating the oral...
NEW YORK, May 15, 2026 Protara Therapeutics, Inc. announced positive updated 12-month data from the fully enrolled BCG-Naïve cohort...
SUZHOU, China, February 26, 2026 ImmVira Group announced encouraging preliminary clinical data for its oncolytic virus candidate MVR-T3011 in...
